The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1…
Browsing: gastric cancer
Digestive cancers therapeutics takes center stage as these cancers—esophageal, gastric, biliary, pancreatic, hepatocellular, and colorectal—account for 33-35% of global cancer…
OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from…
Introduction: Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as detailed in their educational…
We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be…
 Article: Transcript: Question – Please Tell Us About The EA 2142 Trial  So, at ASCO 2022 this year…
 Article: Transcript: Question – Please Tell Us About The 27-gene IO Score Thanks, Stephanie, I appreciate the invitation to…
Audio: Thanks, Stephanie, I appreciate the invitation to interview with you today so I’m going to talk about how the…
DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also…
CheckMate 649: Long-Term Data Support Nivolumab Plus Chemotherapy but Not Nivolumab Plus Ipilimumab in Gastric Cancer This is a study…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…